TRANSCENTA-B: VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON PROMISING ANTI-TUMOR ACTIVITYOF NOVEL FGFR2B TARGETING ADC WITH SITE-SPECIFICCONJUGATED TOPO I INHIBITOR PAYLOAD IN PRECLINICAL TUMOR MODELS AT AACR 2025
TRANSCENTA-B: NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED HOLDERS
TRANSCENTA-B: NOTIFICATION LETTER AND REPLY FORM TO REGISTERED HOLDERS
TRANSCENTA-B: 2024 Environmental, Social and Governance Report
TRANSCENTA-B: 2024 ANNUAL REPORT
TRANSCENTA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2025
TRANSCENTA-B: GRANT OF AWARD SHARES PURSUANT TO THESHARE INCENTIVE SCHEME
TRANSCENTA-B: SUPPLEMENTAL ANNOUNCEMENT
TRANSCENTA-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024;AND CHANGE IN USE OF PROCEEDS
TRANSCENTA-B: DATE OF BOARD MEETING
TRANSCENTA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2025
TRANSCENTA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
TRANSCENTA-B: Next Day Disclosure Returns
TRANSCENTA-B: Next Day Disclosure Returns
TRANSCENTA-B: Change of Address of Principal Place of Business in Hong Kong
TRANSCENTA-B: Next Day Disclosure Returns
TRANSCENTA-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
TRANSCENTA-B: Next Day Disclosure Returns
TRANSCENTA-B: Next Day Disclosure Returns
TRANSCENTA-B: VOLUNTARY ANNOUNCEMENT-BUSINESS UPDATE ON PROMISING ANTI-TUMOR ACTIVITY OF NOVEL LIV-1 TARGETING ADCS WITH SITE-SPECIFIC CONJUGATED TOPO I INHIBITOR PAYLOAD IN TNBC TUMOR MODELS AT 2024 SABCS